Xtant Medical shares jump 10.6% intraday after launching nanOss Strata bone graft with enhanced osteoconductivity.

Xtant Medical (XTNT) surged 10.60% intraday following the announcement of the commercial launch of its next-generation synthetic bone graft, nanOss Strata. The product, designed to mimic human bone structure and enhance osteoconductivity, represents a key innovation in regenerative medicine. The company emphasized its potential to improve surgical outcomes, with preformed and moldable graft options now available through its distribution network. The CEO highlighted the launch as a testament to Xtant’s commitment to innovation, reinforcing investor confidence in the product’s market acceptance and growth potential. The positive price reaction aligns with the strategic significance of the new offering, which is expected to strengthen the company’s position in orthobiologics and spinal solutions.